Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

2025 ARTÍCULOS , VIENDO DEL 1171 AL 1185

TRAILBLAZER-ALZ 4: A phase 3 trial comparing donanemab with aducanumab on amyloid plaque clearance in early, symptomatic Alzheimer's disease

Salloway S, Pain A, Lee E, Papka M, Ferguson MB, Wang H, Hu H, Lu M, Oru E, Ardayfio PA, Hoban DB, Collins EC, Brooks DA, Sims JR.

Alzheimers Dement. 2025 May;21(5):e70293. doi: 10.1002/alz.70293.

Systematic review and meta-analysis of bulk RNAseq studies in human Alzheimer's disease brain tissue

Aguzzoli Heberle B, Fox KL, Lobraico Libermann L, Ronchetti Martins Xavier S, Tarnowski Dallarosa G, Carolina Santos R, Fardo DW, Wendt Viola T, Ebbert MTW.

Alzheimers Dement. 2025 Mar;21(3):e70025. doi: 10.1002/alz.70025.

Clarity AD: Asian regional analysis of a phase III trial of lecanemab in early Alzheimer's disease

Chen C, Katayama S, Lee JH, Lee JY, Nakagawa M, Torii K, Ogawa T, Dash A, Irizarry M, Dhadda S, Kanekiyo M, Hersch S, Iwatsubo T.

J Prev Alzheimers Dis. 2025 May;12(5):100160. doi: 10.1016/j.tjpad.2025.100160. Epub 2025 Apr 5.

Clinical Benefits and Risks of Antiamyloid Antibodies in Sporadic Alzheimer Disease: Systematic Review and Network Meta-Analysis With a Web Application

Jeremic D, Navarro-Lopez JD, Jimenez-Diaz L.

J Med Internet Res. 2025 Apr 7;27:e68454. doi: 10.2196/68454.

Donanemab in preclinical Alzheimer's disease: Screening and baseline data from TRAILBLAZER-ALZ 3

Yaari R, Holdridge KC, Williamson M, Wessels AM, Shcherbinin S, Kotari V, Reiman EM, Tariot PN, Alexander R, Langbaum JB, Sims JR.

Alzheimers Dement. 2025 Sep;21(9):e70662. doi: 10.1002/alz.70662.

Allogeneic mesenchymal stem cell therapy with laromestrocel in mild Alzheimer's disease: a randomized controlled phase 2a trial

Rash BG, Ramdas KN, Agafonova N, Naioti E, McClain-Moss L, Zainul Z, Varnado B, Peterson K, Brown M, Leal T, Kopcho S, Carballosa R, Patel P, Brody M, Herskowitz B, Fuquay A, Rodriguez S, Jacobson AF, Leon R, Pfeffer M, Schwartzbard JB, Botbyl J, Oliva AA Jr, Hare JM.

Nat Med. 2025 Apr;31(4):1257-1266. doi: 10.1038/s41591-025-03559-0. Epub 2025 Mar 10.

Modified titration of donanemab reduces ARIA risk and maintains amyloid reduction

Wang H, Serap Monkul Nery E, Ardayfio P, Khanna R, Otero Svaldi D, Gueorguieva I, Shcherbinin S, Andersen SW, Hauck PM, Engle SE, Brooks DA, Collins EC, Fox NC, Greenberg SM, Salloway S, Mintun MA, Sims JR.

Alzheimers Dement. 2025 Apr;21(4):e70062. doi: 10.1002/alz.70062.

Long-term safety and efficacy of lecanemab in early Alzheimer's disease: Results from the clarity AD open-label extension study

van Dyck CH, Sperling R, Johnson K, Dhadda S, Kanekiyo M, Li D, Gee M, Hersch S, Irizarry M, Kramer L.

Alzheimers Dement. 2025 Dec;21(12):e70905. doi: 10.1002/alz.70905.

Amyloid-Related Imaging Abnormalities With Donanemab in Early Symptomatic Alzheimer Disease: Secondary Analysis of the TRAILBLAZER-ALZ and ALZ 2 Randomized Clinical Trials

Zimmer JA, Ardayfio P, Wang H, Khanna R, Evans CD, Lu M, Sparks J, Andersen S, Lauzon S, Nery ESM, Battioui C, Engle SE, Biffi A, Svaldi D, Salloway S, Greenberg SM, Sperling RA, Mintun M, Brooks DA, Sims JR.

JAMA Neurol. 2025 May 1;82(5):461-469. doi: 10.1001/jamaneurol.2025.0065.

evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer's disease

Cummings JL, Atri A, Feldman HH, Hansson O, Sano M, Knop FK, Johannsen P, León T, Scheltens P.

Alzheimers Res Ther. 2025 Jan 8;17(1):14. doi: 10.1186/s13195-024-01666-7.

Determination of Factors Associated With Urinary Incontinence in Older Individuals With Alzheimer's Disease: A Cross-Sectional Study

Özden F, Özkeskin M, Benzer Z, Uysal İ, Işık Eİ, Başer M.

Psychogeriatrics. 2025 Jul;25(4):e70058. doi: 10.1111/psyg.70058.

Technology readiness among UK-based cognitively unaffected older adults during the COVID-19 pandemic: potential implications for decentralised alzheimer's disease prevention trials

Taylor S, Dunn L, Udeh-Momoh C, Abbott K, Giannakopoulou P, Middleton L, Robinson O, Kalsi J, Kafetsouli D, Ford J.

BMC Geriatr. 2025 Jul 30;25(1):563. doi: 10.1186/s12877-025-06158-3.

[Observational study on the coincidence of Alzheimer's disease and idiopathic normal pressure hydrocephalus: analysis of coincidence, the influence on response to cerebrospinal fluid drainage and cerebrovascular copathology]

Beeke M, Sauer C, Petzold J, Schneider S, Frenzen K, Donix M, Reiß G, Brandt M, Haußmann R.

Nervenarzt. 2025 Dec;96(7):686-695. doi: 10.1007/s00115-025-01808-8. Epub 2025 Feb 27.

Disparities in COVID-19-Related Mortality Among Older Adults With Alzheimer's Disease and Related Dementias: Variations Over Time

Qin Q, Temkin-Greener H, Veazie P, Makineni R, Cai S.

J Appl Gerontol. 2025 Jan;44(1):11-17. doi: 10.1177/07334648241264908. Epub 2024 Jul 20.

Lucid episodes among people with Alzheimer's disease and related dementias and their impact on family caregiver stress and grief (LEAD): protocol for a longitudinal observational study

Griffin JM, Bangerter LR, Kim K, Liu Y, Batthyány A, Birkeland RW, Frangiosa TL, Nosheny RL, Gaugler J, Lapid MI.

BMJ Open. 2025 Jul 10;15(7):e098182. doi: 10.1136/bmjopen-2024-098182.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias